The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol.

Metabolism. 1987 Oct;36(10):949-52.

The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic
triglyceride lipase precedes the decrease in high density lipoprotein2
cholesterol.

Applebaum-Bowden D, Haffner SM, Hazzard WR.

Department of Medicine, University of Washington School of Medicine, Seattle.

Administration of the androgenic anabolic steroid, stanozolol, is associated with
decreased high density lipoprotein (HDL) cholesterol (primarily due to decreased
HDL2 cholesterol) and increased levels of postheparin plasma hepatic triglyceride
lipase (HTGL) activity. Since HTGL appears to play a role in HDL metabolism, we
examined the temporal relationship between these changes. HDL cholesterol
remained stable during the first two days of stanozolol administration, but
decreased 14% (P less than .01) by the third day and 39% (P less than .01) by the
seventh day of stanozolol. HDL2 cholesterol paralleled the total HDL cholesterol
level and remained stable for the first two days, but decreased 22% (P less than
.01) after three days and 71% (P less than .01) after seven days of stanozolol.
In contrast, HTGL increased 62% (P less than .001) during the first day, 161% (P
less than .001) with two days, 230% (P less than .001) with three days of
stanozolol administration, and remained elevated thereafter. Thus, during
stanozolol administration HTGL increased dramatically and clearly before any
change in HDL or HDL2 cholesterol.